Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer

This randomised multicentre trial was conducted to establish the optimal duration of palliative chemotherapy in advanced non-small-cell lung cancer (NSCLC). We compared a policy of three vs six courses of new-generation platinum-based combination chemotherapy with regard to effects on quality of lif...

Descripción completa

Detalles Bibliográficos
Autores principales: von Plessen, C, Bergman, B, Andresen, O, Bremnes, R M, Sundstrom, S, Gilleryd, M, Stephens, R, Vilsvik, J, Aasebo, U, Sorenson, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360695/
https://www.ncbi.nlm.nih.gov/pubmed/17047644
http://dx.doi.org/10.1038/sj.bjc.6603383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360695/
https://www.ncbi.nlm.nih.gov/pubmed/17047644
http://dx.doi.org/10.1038/sj.bjc.6603383

Ejemplares similares